A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of imvotamab in
patients with moderate to severe rheumatoid arthritis who have failed prior therapies.
Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A
placebo is a look-alike substance that contains no active drug